Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results
Verrica Pharmaceuticals (Nasdaq: VRCA) reported its third quarter financial results, revealing a net loss of $12.8 million, or $0.47 per share, compared to a loss of $10.5 million, or $0.42 per share, in Q3 2020. The company has received satisfactory resolution on deficiencies at a contract manufacturing organization from the FDA, allowing them to proceed with the approval process for VP-102, targeting molluscum contagiosum. Additionally, Verrica is advancing LTX-315 for basal cell carcinoma, submitting an IND, and expects to start a Phase 2 trial in early 2022.
- Satisfactory resolution of FDA deficiencies enables progress towards VP-102 approval.
- Recognized $12.0 million in license revenues for 2021, compared to none in 2020.
- Increased general and administrative expenses to $8.0 million, up from $4.6 million in Q3 2020.
- Net loss increased to $12.8 million in Q3 2021 from $10.5 million in Q3 2020.
Contract Manufacturer identified in prior CRL receives satisfactory resolution (VAI) of the facility’s identified deficiencies from the FDA
Verrica is engaging with the FDA on next steps toward potential approval of VP-102 for the treatment of molluscum contagiosum
WEST CHESTER, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2021.
“We are pleased that the issues identified at the CMO unrelated to VP-102 have been successfully resolved, enabling us to move toward approval,” said Ted White, Verrica’s President and Chief Executive Officer. “We remain confident in VP-102’s commercial potential. There is a high unmet medical need for molluscum treatments—the viral skin disease affects approximately 6 million people a year in the U.S., mostly children, and there are no FDA-approved treatments. We look forward to continuing our dialogue with the FDA on the appropriate path forward for approval of VP-102.”
Mr. White continued: “In addition, we are excited to continue the expansion of our portfolio into dermatologic oncology by advancing LTX-315, an oncolytic peptide, into clinical development for the treatment of basal cell carcinoma. Skin cancer is the most common cancer in the U.S., with 5 million diagnoses of basal and squamous cell carcinomas each year. We recently submitted an IND for LTX-315 and look forward to initiating our Phase 2 trial in basal cell carcinoma in the first quarter of 2022.”
Business Highlights and Recent Developments
- On September 20, 2021, Verrica announced that the U.S. Food and Drug Administration (“FDA”) issued a Complete Response Letter (“CRL”) regarding its New Drug Application (“NDA”) for VP-102 (cantharidin
0.7% Topical Solution) for the treatment of molluscum contagiosum (“molluscum”). According to the CRL, the FDA identified deficiencies at a facility of a contract manufacturing organization (“CMO”), which were not specifically related to the manufacturing of VP-102 but instead raised general quality issues at the facility. The FDA did not identify any clinical, safety or product specific Chemistry, Manufacturing, and Controls (“CMC”) deficiencies related to VP-102. Following the CRL, on September 22, 2021 Verrica received a General Advice Letter from the FDA with recommendations to improve YCANTH’s user interface. - On November 5, 2021, Verrica was notified that the inspection of the CMO has been classified as “voluntary action indicated” (“VAI”), is now closed and that the VAI classification will not directly negatively impact FDA’s assessment of the Company’s NDA regarding this CMO. With the satisfactory resolution of the facility inspection, Verrica has engaged the FDA to determine the next steps toward the potential approval of VP-102 for the treatment of molluscum.
- In October 2021, the Company submitted an Investigational New Drug Application (“IND”) for LTX-315, a first-in-class oncolytic peptide, for use in basal cell carcinoma. The Company expects to initiate our Phase 2 trial in basal cell carcinoma in the first quarter of 2022.
Financial Results
Third Quarter 2021 Financial Results
- Research and development expenses were
$3.8 million in the third quarter of 2021, compared to$5.0 million for the same period in 2020. The decrease was primarily attributable to lower CMC (Chemistry, Manufacturing, and Controls) and clinical costs related to Verrica’s development of VP-102 for external genital warts and common warts, partially offset by increased compensation costs. - General and administrative expenses were
$8.0 million in the third quarter of 2021, compared to$4.6 million for the same period in 2020. The increase was primarily driven by increased headcount and other expenses related to pre-commercial activities for VP-102, as well as an increase in insurance, professional fees and other operating expenses. - For the third quarter of 2021, net loss on a GAAP basis was
$12.8 million , or$0.47 per share, compared to a net loss of$10.5 million , or$0.42 per share, for the same period in 2020. - For the third quarter of 2021, non-GAAP net loss was
$11.0 million , or$0.40 per share, compared to a non-GAAP net loss of$9.0 million , or$0.36 per share, for the same period in 2020.
Year-to-Date September 2021 Financial Results
- Verrica recognized license revenues of
$12.0 million for the nine months ended September 30, 2021 related to the Collaboration and License Agreement with Torii Pharmaceutical Col, Ltd. There were no license revenues recognized in 2020. - Research and development expenses were
$12.6 million for the nine months ended September 30, 2021, compared to$13.4 million for the same period in 2020. The decrease was primarily attributable to decreased CMC and clinical costs related to Verrica’s development of VP-102 for molluscum contagiosum, external genital warts, and common warts, partially offset by a one-time$2.3 million milestone payment to Lytix Biopharma AS upon the achievement of a regulatory milestone for LTX-315. - General and administrative expenses were
$21.9 million for the nine months ended September 30, 2021, compared to$14.7 million for the same period in 2020. The increase was primarily a result of expenses related to increased headcount, an increase in insurance, professional fees and other operating costs, and an increase in expenses related to pre-commercial activities for VP-102. - For the nine months ended September 30, 2021, net loss on a GAAP basis was
$25.5 million , or$0.95 per share, compared to a net loss of$29.7 million , or$1.19 per share, for the same period in 2020. - For the nine months ended September 30, 2021, non-GAAP net loss was
$19.8 million , or$0.73 per share, compared to a non-GAAP net loss of$25.6 million , or$1.03 per share, for the same period in 2020. - As of September 30, 2021, Verrica had aggregate cash, cash equivalents, and marketable securities of
$79.5 million . The Company believes that its existing cash, cash equivalents, and marketable securities as of September 30, 2021 will be sufficient to support planned operations into the third quarter of 2022.
Non-GAAP Financial Measures
In evaluating the operating performance of its business, Verrica’s management considers non-GAAP loss from operations, non-GAAP net loss and non-GAAP net loss per share. These non-GAAP financial measures exclude stock-based compensation charges and non-cash interest expense that are required by GAAP. Verrica believes that non-GAAP loss from operations, non-GAAP net loss and non-GAAP net loss per share provides useful information to both management and investors by excluding the effect of certain non-cash expenses and items that Verrica believes may not be indicative of its operating performance, because either they are unusual and Verrica does not expect them to recur in the ordinary course of its business, or they are unrelated to the ongoing operation of the business in the ordinary course. non-GAAP loss from operations, non-GAAP net loss and non-GAAP net loss per share should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. Non-GAAP loss from operations, non-GAAP net loss and non-GAAP net loss per share have been reconciled to the nearest GAAP measure in the tables following the financial statements in this press release.
About VP-102
Verrica’s lead product candidate, VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (
About Molluscum Contagiosum (Molluscum)
There are currently no FDA-approved treatments for molluscum, a highly contagious viral skin disease that affects approximately six million people — primarily children — in the United States. Molluscum is caused by a pox virus that produces distinctive raised, skin-toned-to-pink-colored lesions that can cause pain, inflammation, itching and bacterial infection. It is easily transmitted through direct skin-to-skin contact or through fomites (objects that carry the disease like toys, towels or wet surfaces) and can spread to other parts of the body or to other people, including siblings. The lesions can be found on most areas of the body and may carry substantial social stigma. Without treatment, molluscum can last for an average of 13 months, and in some cases, up to several years.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, visit www.verrica.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include expectations regarding the Verrica’s expectations with regard to the potential approval of the NDA for VP-102 and the potential benefits and potential commercialization of VP-102 for the treatment of molluscum, if approved, interactions with the FDA, the clinical development of Verrica’s VP-102 for additional indications and Verrica’s other product candidates, expectations regarding the initiation of clinical trials for LTX-315, and Verrica’s cash, cash equivalents and marketable securities being sufficient to support planned operations into the third quarter of 2022. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, Verrica’s reliance on third parties over which it may not always have full control, uncertainties related to the COVID-19 pandemic and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2020 and other filings Verrica makes with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
VERRICA PHARMACEUTICALS INC.
Statements of Operations
(unaudited, in thousands except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| License revenue: | $ | - | $ | - | $ | 12,000 | $ | - | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 3,763 | 4,988 | 12,572 | 13,401 | ||||||||||||
| General and administrative | 8,005 | 4,649 | 21,866 | 14,747 | ||||||||||||
| Total operating expenses | 11,768 | 9,637 | 34,438 | 28,148 | ||||||||||||
| Loss from operations | (11,768 | ) | (9,637 | ) | (22,438 | ) | (28,148 | ) | ||||||||
| Interest income | 31 | 69 | 96 | 473 | ||||||||||||
| Interest expense | (1,092 | ) | (918 | ) | (3,198 | ) | (2,042 | ) | ||||||||
| Net loss | $ | (12,829 | ) | $ | (10,486 | ) | $ | (25,540 | ) | $ | (29,717 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.47 | ) | $ | (0.42 | ) | $ | (0.95 | ) | $ | (1.19 | ) | ||||
| Weighted average common shares outstanding, basic and diluted | 27,516,477 | 24,988,939 | 26,884,527 | 24,972,972 | ||||||||||||
VERRICA PHARMACEUTICALS INC.
Selected Balance Sheet Data
(unaudited, in thousands)
| September 30, 2021 | December 31, 2020 | |||||||
| Cash, cash equivalents and marketable securities | $ | 79,495 | $ | 65,470 | ||||
| Total assets | 88,756 | 74,154 | ||||||
| Short term debt | 41,348 | 35,315 | ||||||
| Total liabilities | 47,904 | 41,168 | ||||||
| Total stockholders’ equity | 40,852 | 32,986 | ||||||
VERRICA PHARMACEUTICALS INC.
Reconciliation of Non-GAAP Financial Measures (unaudited)
(in thousands except per share data)
| Three Months Ended September 30, 2021 | |||||||||||||
| Loss from Operations | Net loss | Net loss per share | |||||||||||
| GAAP | $ | (11,768 | ) | $ | (12,829 | ) | $ | (0.47 | ) | ||||
| Non-GAAP Adjustments: | |||||||||||||
| Stock-based compensation – General & Admin (a) | 1,054 | 1,054 | |||||||||||
| Stock-based compensation – Research & Development (a) | 427 | 427 | |||||||||||
| Non-cash interest expense (b) | - | 351 | |||||||||||
| Adjusted | $ | (10,287 | ) | $ | (10,997 | ) | $ | (0.40 | ) | ||||
| Three Months Ended September 30, 2020 | |||||||||||||
| Loss from Operations | Net loss | Net loss per share | |||||||||||
| GAAP | $ | (9,637 | ) | $ | (10,486 | ) | $ | (0.42 | ) | ||||
Non-GAAP Adjustments: | |||||||||||||
| Stock-based compensation – General & Admin (a) | 1,079 | 1,079 | |||||||||||
| Stock-based compensation – Research & Development (a) | 152 | 152 | |||||||||||
| Non-cash interest expense (b) | - | 269 | |||||||||||
| Adjusted | $ | (8,406 | ) | $ | (8,986 | ) | $ | (0.36 | ) | ||||
| Nine Months Ended September 30, 2021 | |||||||||||||
| Loss from Operations | Net loss | Net loss per share | |||||||||||
| GAAP | $ | (22,438 | ) | $ | (25,540 | ) | $ | (0.95 | ) | ||||
Non-GAAP Adjustments: | |||||||||||||
| Stock-based compensation – General & Admin (a) | 3,582 | 3,582 | |||||||||||
| Stock-based compensation – Research & Development (a) | 1,150 | 1,150 | |||||||||||
| Non-cash interest expense (b) | - | 1,058 | |||||||||||
| Adjusted | $ | (17,706 | ) | $ | (19,750 | ) | $ | (0.73 | ) | ||||
| Nine Months Ended September 30, 2020 | |||||||||||||
| Loss from Operations | Net loss | Net loss per share | |||||||||||
| GAAP | $ | (28,148 | ) | $ | (29,717 | ) | $ | (1.19 | ) | ||||
Non-GAAP Adjustments: | |||||||||||||
| Stock-based compensation – General & Admin (a) | 2,938 | 2,938 | |||||||||||
| Stock-based compensation – Research & Development (a) | 543 | 543 | |||||||||||
| Non-cash interest expense (b) | - | 596 | |||||||||||
| Adjusted | $ | (24,667 | ) | $ | (25,640 | ) | $ | (1.03 | ) | ||||
- The effects of non-cash stock-based compensation are excluded because of varying available valuation methodologies and subjective assumptions. Verrica believes this is a useful measure for investors because such exclusion facilitates comparison to peer companies who also provide similar non-GAAP disclosures and is reflective of how management internally manages the business.
- The effects of non-cash interest charges are excluded. Verrica believes such exclusion facilitates an understanding of the effects of the debt service obligations on the Company’s liquidity and comparisons to peer group companies and is reflective of how management internally manages the business.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
Terry Kohler
Chief Financial Officer
484.453.3296
info@verrica.com
William Windham
Solebury Trout
646.378.2946
wwindham@soleburytrout.com
Media:
Zara Lockshin
Solebury Trout
646.378.2960
zlockshin@soleburytrout.com
FAQ
What were the financial results for Verrica (VRCA) in Q3 2021?
What is the current status of VP-102 for molluscum contagiosum?
When does Verrica plan to initiate the Phase 2 trial for LTX-315?
How much did Verrica recognize in license revenues for 2021?
